Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Relapsed/Refractory Follicular Lymphoma
NCT02723071Phase 2Completed
- Sponsor
- Roche
- Start
- May 2005
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of ocrelizumab in follicular lymphoma (FL), sponsored by Roche. Started May 2005; status: completed.
02
Drugs
ocrelizumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02723071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723071.